• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

Novo Nordisk CEO to step down as obesity drug competition intensifies

by May 17, 2025
by May 17, 2025

Novo Nordisk said on Friday that Chief Executive Officer Lars Fruergaard Jørgensen will step down, a decision made jointly with the board as the company confronts mounting competitive and financial pressures.

The changes are being made “in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s share price since mid-2024,” the company said.

The Danish drugmaker said Jørgensen would remain in place “for a period” to help ensure a smooth leadership transition.

A formal search for his successor is underway, with an announcement expected in due course.

Jørgensen’s departure comes at a time when the company’s performance has been under scrutiny.

Shares in the pharmaceutical firm fell by more than 4% following the announcement in Copenhagen, while its US-listed stock dropped 5.61% in premarket trading.

The company’s shares have lost more than 24% of their value so far this year in the US, and close to 35% in Copenhagen.

Meanwhile, Eli Lilly has lost only about 5.8% YTD. Its share price was up by 1.36% in pre-market trading.

In a statement, Novo Nordisk said the decision was the result of internal discussions initiated by the Novo Nordisk Foundation, which considered the merits of accelerating CEO succession.

“Novo Nordisk’s strategy remains unchanged, and the Board is confident in the company’s current business plans and its ability to execute on the plans,” said Chairman Helge Lund.

Jørgensen’s tenure saw early success of Wegovy, Ozempic before Eli Lilly took over

Jørgensen has been with Novo Nordisk since 1991 and took over as CEO in 2017.

Under his leadership, the company cemented its lead in the growing global market for obesity and diabetes treatments, largely thanks to the success of Wegovy and Ozempic.

These drugs contributed to soaring sales and investor enthusiasm, turning Novo Nordisk into one of Europe’s most valuable companies.

However, recent developments have rattled investor confidence.

Eli Lilly’s obesity drug Zepbound has steadily gained traction in the United States, surpassing Wegovy in prescriptions since mid-March.

Meanwhile, results from Novo’s trials for next-generation obesity treatments have fallen short of expectations, casting doubts over the company’s future product pipeline.

Strategic partnerships to defend market share

In response to the competitive threat, Novo Nordisk has pursued several strategic partnerships.

Just a day before the CEO announcement, the company signed a collaboration agreement with biotech firm Septerna, potentially worth up to $2.2 billion.

The partnership aims to discover up to four new obesity therapies, with Septerna eligible for over $200 million in upfront and near-term payments.

Novo has also sought to expand access to its existing treatments through US telehealth firms like Hims & Hers, Ro, and LifeMD.

These partnerships allow for direct-to-patient distribution of Wegovy in the US, amid tighter regulations on compounding pharmacies that previously filled the gap during drug shortages.

Despite these efforts, the CEO transition marks a critical moment for Novo Nordisk as it navigates a more crowded and aggressive market landscape.

The post Novo Nordisk CEO to step down as obesity drug competition intensifies appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Why this investment bank sees more than 30% upside on Meta
next post
Rich List 2025: UK billionaires decline for first time in years amid market turmoil

Related Posts

Opendoor stock plunges 21% after weak forecast: could...

August 7, 2025

Why Upstart stock tanked on Q2 earnings and...

August 7, 2025

GLD ETF analysis: is this gold fund on...

August 7, 2025

Asian markets open: Nikkei flat on US chip...

August 7, 2025

Europe markets open: Stocks rise; Maersk Q2 profit...

August 7, 2025

SoftBank posts strong quarterly profit of around $2.9B...

August 7, 2025

Trump and Putin to meet next week; White...

August 7, 2025

Is America really getting rich off tariff revenue?

August 7, 2025

Israel’s Leviathan gas field secures historic $35B export...

August 7, 2025

Trump’s tariff gamble on chips and drugs could...

August 6, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • What Families Gain at the Dinner Table

    August 7, 2025
  • Superman, Sneaking Snacks into Movies, and the Mystery of Social Order

    August 7, 2025
  • How Telematics Is Reshaping Transportation

    August 7, 2025
  • What Families Gain at the Dinner Table

    August 7, 2025
  • Would Superman Bring Coffee to the Movies?

    August 7, 2025
  • Opendoor stock plunges 21% after weak forecast: could more downside be ahead?

    August 7, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 5

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 6

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 7

    Elon Musk says federal employees must fill out productivity reports or resign

    February 23, 2025

Categories

  • Economy (2,114)
  • Editor's Pick (210)
  • Investing (185)
  • Stock (1,413)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Tata Motors rallies on UK-India FTA hopes...

May 8, 2025

Nikkei 225 Index analysis after the BoJ...

June 17, 2025

RollS-Royce share price forecast: extremely bullish above...

May 7, 2025